Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
Clin. transl. oncol. (Print)
; 16(1): 102-106, ene. 2014. tab, ilus
Article
en En
| IBECS
| ID: ibc-127527
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
PURPOSE: To evaluate the efficacy and toxicity of docetaxel regimen as second-line after failure of a platinum-based chemotherapy. METHODS: Between May 2005 and June 2008, we retrospectively analyzed the data of 22 patients who had evidence of disease progression after one prior platinum-based regimen for metastatic urothelial carcinoma. Patients were treated with two different docetaxel dose schedules: (1) docetaxel 60 mg/m(2) every 21 days for unfit patients or (2) docetaxel 75 mg/m(2) every 21 days for fit patients. RESULTS: Median number of docetaxel cycles was three. Overall disease control rate was 18 %. Of the 22 patients, no patient achieved complete or partial response and four patients had stable disease. Median progression-free survival was 1.67 months and median overall survival was 3.12 months. Neutropenia was the most common adverse event. CONCLUSIONS: This study identifies that docetaxel as second-line chemotherapy has low activity and was associated with significant toxicity (AU)
RESUMEN
No disponible
Buscar en Google
Colección:
06-national
/
ES
Banco de datos:
IBECS
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Carcinoma de Células Transicionales
/
Taxoides
/
Antineoplásicos
Tipo de estudio:
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2014
Tipo del documento:
Article